Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
October 18, 2004
- PRESS SEMINAR
October 18, 2004
- 11 Drugs Including Trisrenox Inj. Approved
October 18, 2004
- Pemetrexed Approved in EU for Two Cancer Indications: Eli Lilly
October 18, 2004
- Criteria for Designating "Prescription Drugs" Proposed
October 18, 2004
- Meet the Leaders (37)
October 18, 2004
- BULLETIN
October 18, 2004
- HPB Presents Issues for Discussion on Drug Distribution Reform
October 18, 2004
- REGULATORY NEWS IN BRIEF
October 18, 2004
- BUSINESS NEWS IN BRIEF
October 11, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 11, 2004
- Annual Business Results
October 11, 2004
- OTC NEWS IN BRIEF
October 11, 2004
- 1st Qtr Business Results
October 11, 2004
- MEDICAL DEVICE NEWS IN BRIEF
October 11, 2004
- Business Forecast
October 11, 2004
- DIAGNOSTIC NEWS IN BRIEF
October 11, 2004
- PMDA to Increase Number, Quality of Reviewers: Mr Miyajima
October 11, 2004
- Drug Costs Increase 0.6 Points to 22.2% in FY2003: Korosho Survey
October 11, 2004
- Korosho Explains Key Points of GVP, GQP GLs
October 11, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…